M&As are going strong and
personalized medicine is a growing force; the two are not always intertwined, but in 2016 things may shift toward them being more so than they have been
We must strive to avoid getting swept up in hype and then forget or minimize existing limitations
and challenges as we try to turn exciting discoveries into life-altering products and services
Idera Pharmaceuticals reports positive data from
ongoing Phase 1/2 clinical trial of toll-like receptor in patients with Waldenström’s macroglobulinemia
Company’s second office in the region will strengthen customer relations
and help develop new business among emerging and established Japanese companies
We’ve updated our Privacy Policy to make it clearer how we use your personal data. Please read our Cookie Policy to learn how we use cookies to provide you with a better experience.